China Securities Regulator Suspends Hisoar Pharmaceutical Reorganization Application
This article was originally published in PharmAsia News
Executive Summary
The China Securities Regulatory Commission has suspended a reorganization application by Hisoar Pharmaceutical, citing alleged illegal disclosure.